-
1
-
-
0000637396
-
Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate
-
Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 1962; 194: 948-9
-
(1962)
Nature
, vol.194
, pp. 948-949
-
-
Thorp, J.M.1
Waring, W.S.2
-
2
-
-
0026480744
-
Relation of triglyceride metabolism and coronary artery disease: Studies in the postpradnial state
-
Patsch JR, Miesenbock G, Hopferweiser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postpradnial state. Arterioscler Throbm 1992; 12: 1336-45
-
(1992)
Arterioscler Throbm
, vol.12
, pp. 1336-1345
-
-
Patsch, J.R.1
Miesenbock, G.2
Hopferweiser, T.3
-
3
-
-
0026065576
-
Plasma triglyceride and coronary heart disease
-
Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14
-
(1991)
Arterioscler Thromb
, vol.11
, pp. 2-14
-
-
Austin, M.A.1
-
4
-
-
0023726344
-
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
-
Manninen V, Elo O, Frick H, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-51
-
(1988)
JAMA
, vol.260
, pp. 641-651
-
-
Manninen, V.1
Elo, O.2
Frick, H.3
-
5
-
-
0027445334
-
Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast
-
Steiner G. Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast. Ann Med 1993; 25 (5): 431-5
-
(1993)
Ann Med
, vol.25
, Issue.5
, pp. 431-435
-
-
Steiner, G.1
-
6
-
-
0030455607
-
Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins
-
Gronholdt ML, Nordestgaard BG, Nielsen TG, et al. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke 1996; 27 (12): 2166-72
-
(1996)
Stroke
, vol.27
, Issue.12
, pp. 2166-2172
-
-
Gronholdt, M.L.1
Nordestgaard, B.G.2
Nielsen, T.G.3
-
7
-
-
0031049146
-
Effect of a single high-fat meal on endothelial function in healthy subjects
-
Vogel RA, Corretti M, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997; 79: 350-4
-
(1997)
Am J Cardiol
, vol.79
, pp. 350-354
-
-
Vogel, R.A.1
Corretti, M.2
Plotnick, G.D.3
-
8
-
-
0021276830
-
Influence of gemfibrozil on metabolism of cholesterol and plasma triglycerides in man
-
Kesaniemi YA, Grundy SM. Influence of gemfibrozil on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984; 251: 2241-6
-
(1984)
JAMA
, vol.251
, pp. 2241-2246
-
-
Kesaniemi, Y.A.1
Grundy, S.M.2
-
9
-
-
0017346450
-
Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia
-
Nikkila EA, Huttunen JK, Ehnbolm C. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 1977; 26: 179-86
-
(1977)
Metabolism
, vol.26
, pp. 179-186
-
-
Nikkila, E.A.1
Huttunen, J.K.2
Ehnbolm, C.3
-
10
-
-
0017274039
-
Gemfibrozil: Effect on serum lipids, lipoproteins, postheparin plasma lipase activities and gulcose tolerance in primary by pertriglyceridemia
-
Nikkila EA, Ylikahri R, Huttunen JK. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and gulcose tolerance in primary by pertriglyceridemia. Proc. R Soc Med 1776; 69 Suppl. 2: 58-63
-
(1776)
Proc. R Soc Med
, vol.69
, Issue.2 SUPPL.
, pp. 58-63
-
-
Nikkila, E.A.1
Ylikahri, R.2
Huttunen, J.K.3
-
11
-
-
0029737127
-
Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days
-
Desager JP, Horsmans Y, Vandenplas C, et al. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 1996; 124 Suppl.: S65-73
-
(1996)
Atherosclerosis
, vol.124
, Issue.SUPPL.
-
-
Desager, J.P.1
Horsmans, Y.2
Vandenplas, C.3
-
12
-
-
0026726877
-
Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome
-
Ooi TC, Simo IE, Yakichuk JA. Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome. Arterioscler Thromb 1992; 12: 1184-90
-
(1992)
Arterioscler Thromb
, vol.12
, pp. 1184-1190
-
-
Ooi, T.C.1
Simo, I.E.2
Yakichuk, J.A.3
-
13
-
-
0019977898
-
Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects
-
Stewart JM, Packard CJ, Lorimer AR, et al. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects. Atherosclerosis 1982; 44: 355-65
-
(1982)
Atherosclerosis
, vol.44
, pp. 355-365
-
-
Stewart, J.M.1
Packard, C.J.2
Lorimer, A.R.3
-
14
-
-
0021853270
-
Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: Effects on metabolism of low-density lipoproteins
-
Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: effects on metabolism of low-density lipoproteins. JAMA 1985; 253: 2398-403
-
(1985)
JAMA
, vol.253
, pp. 2398-2403
-
-
Vega, G.L.1
Grundy, S.M.2
-
15
-
-
0021824527
-
Mechanism of action of gemfibrozil on lipoprotein metabolism
-
Saku K, Gartside PS, Hynd BA, et al. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985; 75: 1702-12
-
(1985)
J Clin Invest
, vol.75
, pp. 1702-1712
-
-
Saku, K.1
Gartside, P.S.2
Hynd, B.A.3
-
17
-
-
0018117095
-
A co-operative trial in the primary prevention of ischaemic heart disease: Report from the Committee of Principal Investigators
-
Oct
-
A co-operative trial in the primary prevention of ischaemic heart disease: report from the Committee of Principal Investigators. Br Heart J 1978 Oct; 40 (10): 1069-118
-
(1978)
Br Heart J
, vol.40
, Issue.10
, pp. 1069-1118
-
-
-
18
-
-
0028243020
-
Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia
-
Larsen ML, Illingworth DR, O'Malley JP. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia. Atherosclerosis 1994; 106 (2): 235-40
-
(1994)
Atherosclerosis
, vol.106
, Issue.2
, pp. 235-240
-
-
Larsen, M.L.1
Illingworth, D.R.2
O'Malley, J.P.3
-
19
-
-
0023262019
-
Bezafibrate: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidemia
-
Monk JP, Todd PA. Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidemia. Drugs 1987; 33: 539-76
-
(1987)
Drugs
, vol.33
, pp. 539-576
-
-
Monk, J.P.1
Todd, P.A.2
-
20
-
-
0018954933
-
Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure
-
Abshagen U, Kosters W, Kaufmann B, et al. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure. Klin Wochenschrift 1980; 58: 889-96
-
(1980)
Klin Wochenschrift
, vol.58
, pp. 889-896
-
-
Abshagen, U.1
Kosters, W.2
Kaufmann, B.3
-
21
-
-
0018380599
-
Disposition pharmacokinetics of bezafibrate in man
-
Abshagen U, Bablok W, Koch K, et al. Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 1979; 16: 31-8
-
(1979)
Eur J Clin Pharmacol
, vol.16
, pp. 31-38
-
-
Abshagen, U.1
Bablok, W.2
Koch, K.3
-
22
-
-
0028110096
-
The fibrates in clinical practice: Focus on micronised fenofibrate
-
Shepherd J. The fibrates in clinical practice: focus on micronised fenofibrate. Atherosclerosis 1994; 110: S55-63
-
(1994)
Atherosclerosis
, vol.110
-
-
Shepherd, J.1
-
23
-
-
0024369220
-
The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate
-
Ferry N, Bernard N, Pozet N, et al. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. Br J Clin Pharmacol 1989; 28: 675-81
-
(1989)
Br J Clin Pharmacol
, vol.28
, pp. 675-681
-
-
Ferry, N.1
Bernard, N.2
Pozet, N.3
-
24
-
-
0016589382
-
Absorption and disposition of 2-[4-(2,2-dichlorocyclopropyl)-phenoxy]-2-methylpropanoic acid. Win 35.833, in rats, monkeys and men
-
Davison C, Benziger D, Fritz A, et al. Absorption and disposition of 2-[4-(2,2-dichlorocyclopropyl)-phenoxy]-2-methylpropanoic acid. WIN 35.833, in rats, monkeys and men. Drug Metab Dispos 1975; 3: 520-4
-
(1975)
Drug Metab Dispos
, vol.3
, pp. 520-524
-
-
Davison, C.1
Benziger, D.2
Fritz, A.3
-
25
-
-
0016582785
-
Pharmacokinetics of drugs in patients with nephrotic syndrome
-
Gugler R, Shoeman DW, Huffman DH, et al. Pharmacokinetics of drugs in patients with nephrotic syndrome. J Clin Invest 1975; 55: 1182-9
-
(1975)
J Clin Invest
, vol.55
, pp. 1182-1189
-
-
Gugler, R.1
Shoeman, D.W.2
Huffman, D.H.3
-
26
-
-
0025128458
-
Fenofibrate: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia
-
Balfour JA, McTavish D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990; 40: 260-90
-
(1990)
Drugs
, vol.40
, pp. 260-290
-
-
Balfour, J.A.1
McTavish, D.2
Heel, R.C.3
-
27
-
-
0019968477
-
Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure
-
Desager JP, Costermans J, Verberckmoes R, et al. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 1982; 31: 51-4
-
(1982)
Nephron
, vol.31
, pp. 51-54
-
-
Desager, J.P.1
Costermans, J.2
Verberckmoes, R.3
-
29
-
-
0018214469
-
Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers
-
Desager JP, Harvengt C. Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol Biopharm 1978; 16: 570-4
-
(1978)
Int J Clin Pharmacol Biopharm
, vol.16
, pp. 570-574
-
-
Desager, J.P.1
Harvengt, C.2
-
31
-
-
0022974507
-
In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: Interactions with other drugs
-
Hamberger C, Barre J, Zini R, et al. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res 1986; 6: 441-9
-
(1986)
Int J Clin Pharmacol Res
, vol.6
, pp. 441-449
-
-
Hamberger, C.1
Barre, J.2
Zini, R.3
-
33
-
-
0027536797
-
Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. II: Multiple-dose administration and chronopharmacokinetics
-
Vens-Cappell B, Berndt P, Hilgenstock C, et al. Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. II: multiple-dose administration and chronopharmacokinetics. Arzneimittel Forschung 1993; 43: 351-6
-
(1993)
Arzneimittel Forschung
, vol.43
, pp. 351-356
-
-
Vens-Cappell, B.1
Berndt, P.2
Hilgenstock, C.3
-
34
-
-
0027413864
-
Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. I: Single-dose administration
-
Vens-Cappell B, Hilgenstock C, Gellert M, et al. Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. I: single-dose administration. Arzneimittel Forschung 1993; 43: 346-50
-
(1993)
Arzneimittel Forschung
, vol.43
, pp. 346-350
-
-
Vens-Cappell, B.1
Hilgenstock, C.2
Gellert, M.3
-
35
-
-
0027363780
-
A comparison of the bioavailability of standard or micronized formulations of fenofibrate
-
Guichard JP, Levy-Prades Sauron R. A comparison of the bioavailability of standard or micronized formulations of fenofibrate. Curr Ther Res 1993; 54: 610-4
-
(1993)
Curr Ther Res
, vol.54
, pp. 610-614
-
-
Guichard, J.P.1
Levy-Prades Sauron, R.2
-
36
-
-
6844261317
-
-
Fournier Pharma Inc., Montreal (Canada)
-
Lipidil product monograph. Fournier Pharma Inc., Montreal (Canada), 1990
-
(1990)
Lipidil Product Monograph
-
-
-
37
-
-
1842605278
-
Effect of time of dosing on the pharmacokinetics of a controlled-release gemfibrozil tablet (Lopid SR)
-
Cook JA, Rajagopalan R, Eldon MA, et al. Effect of time of dosing on the pharmacokinetics of a controlled-release gemfibrozil tablet (Lopid SR). Pharmacol Res 1991; 8 Suppl.: S296
-
(1991)
Pharmacol Res
, vol.8
, Issue.SUPPL.
-
-
Cook, J.A.1
Rajagopalan, R.2
Eldon, M.A.3
-
38
-
-
1842448530
-
Gemfibrozil pharmacokinetics after multiple-dose administration of controlled-release (Lopid SR) and conventional (Lopid) tablets
-
Cook JA, Eldon MA, Gibson DM, et al. Gemfibrozil pharmacokinetics after multiple-dose administration of controlled-release (Lopid SR) and conventional (Lopid) tablets. Pharmacol Res 1992; 9 Suppl.: S325
-
(1992)
Pharmacol Res
, vol.9
, Issue.SUPPL.
-
-
Cook, J.A.1
Eldon, M.A.2
Gibson, D.M.3
-
39
-
-
0028576943
-
Interactions of warfarin with drugs and food
-
see comments in: ACP J Club 1995; 122 (2): 44.
-
Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food [see comments in: ACP J Club 1995; 122 (2): 44]. Ann Intern Med 1994; 121 (9): 676-83
-
(1994)
Ann Intern Med
, vol.121
, Issue.9
, pp. 676-683
-
-
Wells, P.S.1
Holbrook, A.M.2
Crowther, N.R.3
-
40
-
-
0023677227
-
Gemfibrozil: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia
-
Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs 1988; 36: 314-39
-
(1988)
Drugs
, vol.36
, pp. 314-339
-
-
Todd, P.A.1
Ward, A.2
-
41
-
-
0025104039
-
Gemfibrozil interaction with warfarin sodium (coumadin)
-
Ahmad S. Gemfibrozil interaction with warfarin sodium (coumadin). Chest 1990; 98: 1041-2
-
(1990)
Chest
, vol.98
, pp. 1041-1042
-
-
Ahmad, S.1
-
42
-
-
0026514173
-
Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction
-
Blum A, Livneh A, Seligmann H. Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction. Isr J Med Sci 1992; 28: 47-9
-
(1992)
Isr J Med Sci
, vol.28
, pp. 47-49
-
-
Blum, A.1
Livneh, A.2
Seligmann, H.3
-
43
-
-
0017816548
-
Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus
-
Ferrari C, Romussu M, Testori GP, et al. Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus. Biomedicine 1978; 29: 133-6
-
(1978)
Biomedicine
, vol.29
, pp. 133-136
-
-
Ferrari, C.1
Romussu, M.2
Testori, G.P.3
-
45
-
-
0026083568
-
Gemfibrozil: Interaction with glyburide
-
Ahmad S. Gemfibrozil: interaction with glyburide. South Med J 1991; 84: 102
-
(1991)
South Med J
, vol.84
, pp. 102
-
-
Ahmad, S.1
-
46
-
-
0025365041
-
Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
-
Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5
-
(1990)
JAMA
, vol.264
, pp. 71-75
-
-
Pierce, L.R.1
Wysowski, D.K.2
Gross, T.P.3
-
47
-
-
0028962401
-
Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
-
Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13
-
(1995)
Eur Heart J
, vol.16
, pp. 5-13
-
-
Shepherd, J.1
-
48
-
-
0029042641
-
Pharmacokinetics of the combination of fluvastatin and gemfibrozil
-
Spence JD, Munoz CE, Hendricks L. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80-3
-
(1995)
Am J Cardiol
, vol.76
, pp. 80-83
-
-
Spence, J.D.1
Munoz, C.E.2
Hendricks, L.3
-
49
-
-
0029166810
-
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
-
Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995; 52 (15): 1639-45
-
(1995)
Am J Health Syst Pharm
, vol.52
, Issue.15
, pp. 1639-1645
-
-
Garnett, W.R.1
-
50
-
-
0029758869
-
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
-
Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61
-
(1996)
Clin Pharmacol Ther
, vol.60
, pp. 54-61
-
-
Neuvonen, P.J.1
Jalava, K.-M.2
-
51
-
-
12644251055
-
Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
-
Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-21
-
(1997)
Clin Pharmacol Ther
, vol.62
, pp. 311-321
-
-
Olbricht, C.1
Wanner, C.2
Eisenhauer, T.3
-
52
-
-
0028846142
-
In vivo inhibition profile of cyctochrome P450TB (CYP2C9) by (+/-)-fluvastatin
-
Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cyctochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995; 58 (4): 412-7
-
(1995)
Clin Pharmacol Ther
, vol.58
, Issue.4
, pp. 412-417
-
-
Transon, C.1
Leemann, T.2
Vogt, N.3
-
53
-
-
0027321524
-
Biotransformation of pravastatin sodium (I): Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium
-
Kitazawa E, Tamura N, Iwabuchi H, et al. Biotransformation of pravastatin sodium (I): mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993; 192: 597-602
-
(1993)
Biochem Biophys Res Commun
, vol.192
, pp. 597-602
-
-
Kitazawa, E.1
Tamura, N.2
Iwabuchi, H.3
-
54
-
-
0030944304
-
Drug interactions with grapefruit: Whose responsibility is it to warn the public?
-
Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997; 61: 395-400
-
(1997)
Clin Pharmacol Ther
, vol.61
, pp. 395-400
-
-
Spence, J.D.1
-
55
-
-
0023929374
-
Rhabdomyolysis and renal injury with lovastatin use: Report of two cases in cardiac transplant recipients
-
Corpier CI, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-41
-
(1988)
JAMA
, vol.260
, pp. 239-241
-
-
Corpier, C.I.1
Jones, P.H.2
Suki, W.N.3
-
56
-
-
0023860312
-
Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
-
East C, Alivizatos PA, Grundy SC, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47-8
-
(1988)
N Engl J Med
, vol.318
, pp. 47-48
-
-
East, C.1
Alivizatos, P.A.2
Grundy, S.C.3
-
57
-
-
0029126528
-
Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
-
Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664-5
-
(1995)
N Engl J Med
, vol.333
, pp. 664-665
-
-
Lees, R.S.1
Lees, A.M.2
-
59
-
-
0029089702
-
Ketoconazole to reduce the need for cyclosporine after cardiac transplantation
-
Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628-33
-
(1995)
N Engl J Med
, vol.333
, pp. 628-633
-
-
Keogh, A.1
Spratt, P.2
McCosker, C.3
-
60
-
-
0026099498
-
Interaction of citrus juices with felodipine and nifedipine
-
Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9
-
(1991)
Lancet
, vol.337
, pp. 268-269
-
-
Bailey, D.G.1
Spence, J.D.2
Munoz, C.3
-
61
-
-
0028153858
-
Grapefruit juice and drugs: How significant is the interaction?
-
Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26 (2): 91-8
-
(1994)
Clin Pharmacokinet
, vol.26
, Issue.2
, pp. 91-98
-
-
Bailey, D.G.1
Arnold, J.M.O.2
Spence, J.D.3
-
62
-
-
0030897505
-
Grapefruit juice: Terfenadine single-dose interaction: magnitude, mechanism, and relevance
-
Rau SE, Bend JR, Arnold MO, et al. Grapefruit juice: terfenadine single-dose interaction: magnitude, mechanism, and relevance. Pharmacokinet Drug Dispos 1997; 61: 401-9
-
(1997)
Pharmacokinet Drug Dispos
, vol.61
, pp. 401-409
-
-
Rau, S.E.1
Bend, J.R.2
Arnold, M.O.3
-
63
-
-
0029782647
-
Erythromycin-felodipine interaction: Magnitude, mechanism and comparison with grapefruit juice
-
Jul
-
Bailey DG, Bend JR, Arnold JMO, et al. Erythromycin-felodipine interaction: magnitude, mechanism and comparison with grapefruit juice. Clin Pharmacol Ther 1996 Jul; 60 (1): 25-33
-
(1996)
Clin Pharmacol Ther
, vol.60
, Issue.1
, pp. 25-33
-
-
Bailey, D.G.1
Bend, J.R.2
Arnold, J.M.O.3
|